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rs, visualized with rhodamiClinical
isease status Healthy/Unaffected
aryotype (aCGH) Decreased copy number at 2q37.3 and 3q25.1. Both are
considered to be benign copy number variants.
NP Array Gain on chromosome 18q23 Canham et al. ( 2015)
NA ﬁngerprint Allele sizes (in bp) of 16 microsatellite markers speciﬁc
for chromosomes 13, 18 and 21 Jacquet et al. (2013)
LA typing HLA-A 02,03; B 35,40; Bw 06; C 03,04; DRB1 01,13;
DRB3 03; DQB1 05,06 Jacquet et al. (2013) Canham et al.
(2015)iability testing Pass
ycoplasma Negative
erility Pass
luripotent markers
(immunostaining)
(Fig. 1)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityhree germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)ibling lines available NoSWe generated KCL037 clinical grade hESC line following protocols
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed decreased copy number at 2q37.3
(242,930,599–242,948,040) and 3q25.1 (151,368,847–151,542,568).
The imbalances identiﬁed are considered to be benign copy number
variants. The chromosome 3 imbalance was not “called” by software.
Whole-genome single nucleotide polymorphism (SNP) array analy-
sis revealed a 542 kb gain on chromosome 18q23 in KCL037 containing
two coding genes, SALL3 and ATP9B (Canham et al., 2015). A smaller du-
plication (nsv577794) covering the same two genes has been reported
previously (Cooper et al., 2011).
The KCL037 line is conﬁrmed by PCR to be negative for Cytomegalo-
virus (CMV), Human T-Cell Lymphotropic Virus 1 (HTLV1), Human
Immunodeﬁciency Virus 1 (HIV1), Hepatitis C Virus (HepC, HCV),
Hepatitis B Virus (HepB, HBV) and Epstein–Barr virus (EBV), also called
human herpesvirus 4 (HHV4). The testing has been performed by The
Doctors Laboratory London.
We also generated research grade of KCL037 line that is adapted to
feeder-free conditions.cy markers. Pluripotency is conﬁrmed by immunostaining (Oct
ne-phalloidin (red), are present in both feeders and hES cell co3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 – R.4 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Sep. 22, 2009. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 7 – R.4. HFEA
Code of Practice Edition 7 – R.4was in effect: 02Oct. 2008–30 Sep. 2009.3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.3.4. Viability test
Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
lonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
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Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed in
vitro and in vivo as described (Petrova et al., 2014; Stephenson et al., 2012).
3.7. Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in detail (Ilic et al., 2012).
3.9. SNP array
SNP array was performed as described in detail (Canham et al.,
2015).
3.10. HLA typing
HLA-A,−B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
HLA typing was also performed independently by other group
(Canham et al., 2015).Author disclosure statement
There are no competing ﬁnancial interests in this study.
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